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Abstract: Patient-reported outcomes (PROs) can be included in clinical trials as primary or 
secondary endpoints and are increasingly recognized by regulators, clinicians, and patients as 
valuable tools to collect patient-centered data. PROs provide unique information on the impact 
of a medical condition and its treatment from the patient’s perspective; therefore, PROs can be 
included in clinical trials to ensure the impact of a trial intervention is comprehensively assessed. 
This review first discusses examples of how PRO endpoints have added value to clinical trial 
interpretation. Second, it describes the problems with current practices in designing, implement-
ing, and reporting PRO studies, and how these problems may be addressed by complying with 
guidance for protocol development, selecting appropriate PRO measures to match clinically 
motivated PRO hypotheses, minimizing the rates of avoidable missing PRO data, analyzing and 
interpreting PRO data, and transparently reporting PRO findings.
Keywords: patient-reported outcomes, quality of life, trial conduct, research practices, clinical 
trials as topic
Introduction
Patient-reported outcomes (PROs) are defined as “any report of the status of a patient’s 
health condition that comes directly from the patient, without interpretation of the 
patient’s response by a clinician or anyone else” (Food and Drug Administration 
[FDA], p. 6).1 PRO is an umbrella term which may refer to patient-reported: 1) disease 
symptoms or treatment side effects, such as pain, fatigue, or anxiety; 2) functional 
outcomes such as physical, sexual, social, role, emotional, or cognitive functioning; or 
3) multidimensional constructs such as health-related quality of life (HRQOL) or health 
utility. HRQOL is defined as “the subjective assessment of the impact of disease and 
treatment across the physical, psychological, social and somatic domains of function-
ing and well-being” (Revicki et al, p. 888).2 In the present review, we focus on PROs 
as clinical trial endpoints and differentiate PROs from other types of patient-reported 
data, such as patient-reported experiences or patient-reported behaviors, which may 
also be included as clinical trial endpoints.
PROs are assessed in trials using questionnaires, often referred to as “PRO mea-
sures.” Validated PRO measures are used in clinical trials, as opposed to asking partici-
pants open-ended questions about their outcomes, to ensure that the questions, response 
options, and the general approach to assessment are standardized for all participants. 
This enables the research team to attribute any differences between patient responses 
to real differences in perceptions of their outcomes, as opposed to methodological 
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differences or biases. PRO measures are typically developed 
with input from clinicians, patients, and psychometric experts 
to ensure that the PRO measure assesses clinically relevant 
issues that are meaningful to patients in a robust manner.
PROs provide unique information on the impact of a 
medical condition and its treatment from the patients’ per-
spective;3,4 therefore, PROs can be included as trial endpoints 
to ensure that the impact of a trial intervention is compre-
hensively assessed. In palliative care or rehabilitation trials, 
PROs may be the primary endpoint of interest. In other trials, 
they may be included as secondary endpoints to support and 
help interpret the primary endpoint. In some contexts, PROs 
may be included as exploratory or tertiary endpoints, with the 
intention of generating hypotheses for testing in future stud-
ies. Including PROs in a clinical trial requires careful thought 
regarding the specific research questions to be addressed and 
the needs of all stakeholders, including patients, clinicians, 
trial sponsors, and regulatory authorities.
importance of including PROs in clinical 
trials
increased use and recognition of PROs
The use of PROs in clinical trials has increased over time. 
Consecutive reviews of ClinicalTrials.gov in 2004–20075 
and 2007–20136 determined that use of PRO endpoints had 
increased from 14% to 27% of trials over that period. A more 
recent review of the Australian New Zealand Clinical Trials 
Registry determined that 45% of trials registered from 2005 
to March 2017 included PROs and had a strong increase in the 
proportion of trials with PROs registered over time (r=0.74, 
P=0.009).7 Similarly, between 2000 and 2015, the Center for 
Devices and Radiological Health reported an increase of over 
500% in pre-market submissions including PRO measures.8
Increases in the use of PROs in clinical trials may be 
attributable to top-down encouragement from professional 
societies and regulatory bodies.9 In oncology, for example, 
the American Society of Clinical Oncology (ASCO)10 and 
European Society for Medical Oncology (ESMO)11 have 
proposed standardized approaches to evaluate clinical trial 
results by using scores to evaluate the Magnitude of Clinical 
Benefit (ESMO MCB) or the Net Health Benefit (ASCO), 
which include survival endpoints in addition to toxicity and 
HRQOL.10,11 The ESMO MCB scores based on survival out-
comes are upgraded if there is evidence to indicate improved, 
or delayed deterioration in, HRQOL using validated PRO 
measures or a substantial reduction in adverse events. The 
ESMO and ASCO recommendations are clearly important 
in evaluating new therapies and highlight the importance of 
including PRO endpoints in clinical trials.
Furthermore, the Australian government supports a 
Quality of Life Office to work with the 13 National Cancer 
Clinical Trials Groups to include PRO endpoints in inves-
tigator-initiated oncology trials.12 The European Medicines 
Agency released guidance in 2016 on the use of PROs in the 
evaluation of anti-cancer medicinal products.13 PROs have 
also been highlighted by professional oncology societies as 
important endpoints in specific oncology trial contexts, for 
example, in ovarian cancer clinical trials.14–17
Beyond oncology, the FDA-released guidance in 2009 on 
the evaluation of PRO measures used to support medical prod-
uct labeling claims. This guidance aimed to improve the effi-
ciency and transparency of discussions between sponsors and 
the FDA during the drug development process, to streamline the 
FDA’s review of PRO measures and associated clinical trial data, 
and to improve methods for considering patients’ perspectives 
in the medical product review process.1 The Organization for 
Economic Co-operation and Development recently highlighted 
the importance of collecting PROs to enable a more complete 
understanding of health system performance.4 In 2017, the 
Medicare Evidence Development and Coverage Advisory Com-
mittee, USA, determined that quality of life (QOL) measures 
were of particular interest and should be included as health 
outcomes in future heart failure studies.8,18
what value do PROs add to clinical trials?
Au et al3 reviewed Phase III oncology cancer trials led by the 
National Cancer Institute of Canada Clinical Trials Group and 
classified the benefits of including a PRO as a trial endpoint 
into three categories. First, PROs may assist clinicians and 
future patients to select the best treatment by providing a 
clearer picture of the costs and benefits of treatment.3 Second, 
PRO data can enrich our understanding of the patients’ experi-
ence with unique information that could not be gained from 
biomedical outcomes alone, as certain domains are difficult 
to observe (eg, pain and fatigue) and outcomes such as the 
degree of symptom bother are subjective and best collected 
through patient report.3 Third, PROs can help to improve 
future clinical trial methods.3 In contexts where certain PROs 
have confirmed prognostic significance, PROs can be used 
to stratify participants. Furthermore, careful examination 
of PRO assessment compliance can illuminate areas where 
methodological improvement is needed.3
Other applications of PRO data include informing regu-
latory decisions, cost-effectiveness analyses, and informing 
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clinical guidelines and health policy. Patient advocacy groups 
promote the use of PROs as they enable patients to communi-
cate their experience, assess whether their experience aligns 
with their expectations of treatment, and highlight any unmet 
needs or care areas that are in need of improvement.19 For 
these reasons, patient advocates are vocal about the impor-
tance of including PROs.19,20 In an era where consumer input 
into clinical trial protocols is highly valued and encouraged, 
advocacy for PRO endpoints may result in increased imple-
mentation of PRO endpoints in clinical trials.
examples of how PROs have contributed to the 
interpretation of clinical trial results
Investigators should determine primary and secondary trial 
endpoints a priori according to what is appropriate for the 
interpretation of the individual clinical trial. As a secondary 
endpoint, PRO data add information to assist the interpreta-
tion of primary trial endpoints. In other clinical contexts, 
it may be appropriate for the PRO to be the primary trial 
endpoint. There is no “one-size” approach to interpret PRO 
data, and all clinical trial data including PROs should be 
interpreted in context. There are numerous examples where 
PRO data, interpreted in conjunction with other trial out-
comes, have been fundamental in understanding patients’ 
perceptions of the risks and benefits of treatment and have 
impacted the interpretation of the trial results.
A clinical trial comparing prednisone with or without 
mitoxantrone in men with metastatic prostate cancer found 
that although there was no difference in overall survival 
(P=0.27), or serum prostate-specific antigen levels (P=0.11) 
between the two arms,21 the patients receiving mitoxantrone 
experienced significant improvement in PROs. The primary 
outcome was palliation of pain (response defined as a 2-point 
reduction in the 6-point pain intensity scale of the McGill-
Melzack Pain Questionnaire, or complete loss of pain if the 
patient initially scored >1, maintained on two consecutive, 
three-weekly evaluations, without an increase in analgesic 
score.) Response rates were 29% (95% CI: 19%, 40%) in the 
mitoxantrone + prednisone group and 12% (95% CI: 6%, 
22%) in the prednisone alone group (P=0.01). Furthermore, 
pain (severity, impact, and relief), fatigue, mood, aspects of 
functioning, global QOL, and other PROs improved with 
mitoxantrone + prednisone from the baseline (P<0.01).21,22 
The PRO endpoints led to regulatory approval of mitoxan-
trone for this indication and wide implementation in the 
clinic.
In a trial of ruxolitinib compared to placebo for the treat-
ment of intermediate- or high-risk myelofibrosis, ruxolitinib 
was found to improve fatigue, as assessed by the Patient 
Reported Outcomes Measurement Information System 
(PROMIS) Fatigue 7-item short form.23 PROMIS Fatigue 
is included on the ruxolitinib label accordingly, along with 
PRO data from previous studies which demonstrated that 
ruxolitinib was associated with a greater proportion of 
patients experiencing a reduction of ≥50% in patient-reported 
myelofibrosis symptoms (abdominal discomfort, pain under 
left ribs, early satiety, night sweats, itching, bone/muscle 
pain, and inactivity), as well as significant improvement 
(P<0.001) in these symptoms until 20 weeks, and until 24 
weeks for abdominal discomfort, early satiety, and itching. 
Conversely, the placebo arm experienced a steady decline 
across all myelofibrosis symptoms over the 24 weeks.23,24
Gnanasakthy et al have published a series of papers 
detailing the FDA labels that include PRO data that sup-
port regulatory approvals.25–27 Between 2006 and 2010, 28 
of 116 (24%) products approved by the FDA were granted 
PRO claims. Of these products, 71% included a PRO as the 
primary trial endpoint, and pain-related endpoints were most 
common (38%).27 Between 2011 and 2015, 30 of the 182 
(17%) new drugs approved by the FDA received PRO label-
ing. Again, many of these trials had primary PRO endpoints 
(77%).26 Between 2010 and 2014, 40 drugs were approved 
by the FDA Office of Hematology and Oncology products, 
of which three (8%) were granted PRO labeling.25 A further 
13 oncology trials included PROs on the Drug Approval 
Package (“a summary of clinical study reports and related 
documents written by the FDA staff after data from pivotal 
studies submitted by the study sponsors has been reviewed”) 
(Gnanasakthy et al,25 p. 2), but did not receive PRO label-
ing due to various reasons, including inappropriate choice 
of PRO measure, high rates of missing PRO data, and poor 
reporting of PROs.25
Strategies for future optimization
In this section, we summarize the current challenges with 
PRO use in trials and present solutions and guidance to 
address these issues.
Protocol development
issues with current practice
There is good evidence that trial protocols are often incom-
plete with regard to PRO endpoints. A review of 75 trial 
protocols (all clinical areas) with PRO endpoints submitted 
to the United Kingdom (UK) National Institute for Health 
Research (NIHR) Health Technology Assessment program in 
2012–2013 determined that only 8% of the 75 trials studied 
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described a rationale for PRO assessment, 60% addressed 
PRO-specific quality assurance issues, and only 8% offered 
PRO data collection instructions.28 Overall, the protocols 
addressed a mean of 33% of recommended PRO items.28
A second review examined the PRO content of 26 proto-
cols of Phase III international, ovarian cancer trials published 
between 2000 and 2016 against a list of PRO-specific items 
that would eventually inform the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT)-PRO 
Extension.29,30 Of the 26 trials, one had a co-primary PRO 
endpoint, and 25 had secondary PRO endpoints. This review 
demonstrated that overall coverage of recommended PRO 
items ranged from 8% to 66% (mean coverage 28%). More 
than half of the recommended and applicable items were 
addressed by only two protocols. Basic aspects of PRO 
research design, including the primary/secondary status of 
the PRO endpoints and assessment schedules, were addressed 
in the majority of ovarian cancer trial protocols: as 92% 
and 96%, respectively. However, key guidance about PRO 
administration and quality assurance was often incomplete 
or omitted. For example, only 23% of these trial protocols 
specified time windows for each scheduled PRO assess-
ment.30 Assessment windows are particularly important in 
trials of chemotherapy because of its fluctuating and transient 
side effects. If the PRO assessment seeks to capture the acute 
impact of chemotherapy on HRQOL, the time windows 
specified in the protocol should capture the days where the 
effects of chemotherapy toxicity would be felt. Without time 
windows, trial staff may not realize the time-sensitive nature 
of the scheduled assessment, which may lead to uninforma-
tive PRO data or biased interpretation if the time window is 
missed. Further trial staff who do not administer the PRO 
measure on the targeted date may not realize that they could 
validly continue to pursue that PRO assessment for a few 
more days, leading to that PRO assessment being missed.
In addition, only 31% of protocols specified a PRO-
specific objective and only 19% included a PRO hypothesis.30 
This is poor practice and makes it difficult to assess whether 
the PRO study was designed around a clinically motivated 
and relevant research question, and whether the chosen PRO 
measures and assessment time points were appropriate and 
would provide meaningful data for subsequent interpretation 
of the trial findings alongside other clinical endpoints.
These examples illustrate the importance of providing 
clear and comprehensive PRO study content in trial proto-
cols, as this ensures that high-quality data are collected using 
consistent data collection methods to inform any clinical 
recommendations resulting from the trial.
A third study is in progress which will review the PRO 
content of cancer trials (all cancers) submitted to the UK 
NIHR Portfolio;31 however, at the time of this review, the 
results were yet to be published.
PRO-specific protocol guidance
The SPIRIT statement was published in 201332,33 and provided 
an evidence-based list of items recommended for inclusion 
in trial protocols. Until recently, no such consensus-based 
guidance for PROs existed. In 2018 the SPIRIT-PRO guid-
ance was released.29 SPIRIT-PRO is the product of years 
of methodological research. It was developed based on an 
international, expert consensus process that aimed to identify 
the essential items to include in PRO sections of clinical trial 
protocols. It should be used in conjunction with the SPIRIT 
2013 statement32,33 when developing a research protocol for 
a trial with a primary or important secondary PRO endpoint. 
SPIRIT-PRO contains 16 items, 11 of which are new, PRO-
specific “extensions” to the core SPIRIT 2013 checklist, 
and five PRO-specific “elaborations” on existing SPIRIT 
2013 items. The SPIRIT-PRO Extension items address the 
PRO study rationale, objectives, eligibility criteria, PRO 
domains used to evaluate the intervention, assessment time 
points, selection of PRO measures, measurement proper-
ties of these PRO measures, the PRO data collection plan, 
translation of PRO measures to other languages, proxy 
completion, strategies to minimize missing PRO data, and 
whether PRO data will be monitored during the active trial 
phase to inform the clinical care of participants.29 The full 
checklist is available in the SPIRIT-PRO publication29 and on 
the EQUATOR (Enhancing the QUAlity and Transparency 
Of health Research) Network website.34
Appropriate choice of PROs and PRO 
measures
issues with current practice
The suitability of PRO measures to address pre-specified 
hypotheses was evaluated in 66 head and neck cancer and 
thyroid (HNT) cancer clinical trials published between 2004 
and 2015 (22 with primary PRO endpoints, 44 with second-
ary PRO endpoints).35 This study found that only eight of 
the 66 studies (12%) reported a PRO hypothesis, and eight 
of these chose an appropriate PRO measure, which assessed 
and produced scores for the constructs specified in their 
hypotheses. While the sample size was small (n=8), the result 
suggested that explicitly specifying a PRO hypothesis a priori 
engaged investigators to carefully consider the constructs of 
particular relevance to their clinical population and to select 
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appropriate PRO measures. PRO measures that are not suited 
to the specific research question cannot yield the required 
information, resulting in a waste of resources and time in 
collecting PRO data. It is concerning that 58 (88%) of the 
HNT randomized controlled trials (RCTs) failed to report any 
PRO hypotheses, precluding assessment of the suitability of 
their chosen PRO measures.35
Furthermore, five (8%) of the 66 HNT RCT publications 
did not name the PRO measure that had been used. Many 
more RCTs modified validated PRO measures without 
specifying the nature of the modifications.35 Modifications 
may have involved rewording, removing or adding items, 
or altering scoring procedures and may have compromised 
the psychometric properties of the PRO measures. None of 
these RCTs assessed the impact of these modifications on the 
psychometric integrity and performance of the measure. A 
follow-on issue is that the publication of RCTs using modi-
fied questionnaires may set a precedent for future RCTs to 
use the modified version rather than the validated version, 
thereby potentially perpetuating the problem of use of poor 
quality PRO measures.
As noted earlier, the FDA has declined to provide PRO 
labeling on the basis that clinical trials have not selected 
an appropriate PRO measure or that the measure had not 
been appropriately developed and validated.25 This suggests 
that the problem occurs even among well-funded and well-
resourced trials presented to the FDA.
Guidance available for the selection of PRO 
measures
Clinicians, patients, researchers, and other relevant stake-
holders should be involved in discussions about important, 
clinically relevant PROs and, corresponding appropriate and 
valid PRO measures. Kluetz et al state that “The goal [of 
PRO measure selection] should be to achieve a comprehen-
sive evaluation of the patient experience most affected by 
the therapy, while maximizing the relevance of individual 
questions and minimizing overall burden and duplication” 
(p. 1557).36
Snyder et al describe how to develop a measurement 
strategy for prospective labeling claims.37 This involves 
identifying relevant PRO domains, developing a conceptual 
framework around these domains, identifying approaches 
to measure these domains, and designing a measurement 
strategy based on this information. Snyder acknowledges that 
existing scales may not fit the purpose of some studies and 
advocates that modifications to PRO measures should be sub-
ject to reliability and validity tests prior to implementation.37
Luckett and King describe six guiding principles toward 
selecting a PRO measure in cancer clinical research; however, 
the principles apply more broadly. These principles state that 
researchers should
1. consider PRO measures early in the study design,
2. select a primary PRO that is proximal to the disease or 
treatment (ie, symptoms or direct treatment side effects 
as opposed to down-stream impact on HRQOL),
3. ensure that the PRO items (individual questions) are 
appropriate to the study and consider how the items 
combine into summary scales,
4. appraise evidence regarding the reliability and validity 
of the PRO measure,
5. consider practicalities such as respondent burden, mode 
of administration, and the need for validated language 
translations, and
6. take a minimalist approach to ad hoc items, that is, avoid 
adding to or modifying existing PRO measures.38
As these guidelines demonstrate, trial investigators are 
increasingly being encouraged to measure proximal PROs, 
such as symptoms, in preference to measuring more distal 
or multidimensional constructs such as HRQOL, as primary 
PRO endpoints. This is because more distal domains are more 
likely to be influenced by factors beyond the trial interven-
tions, such as social context and other life events. The FDA 
advises against HRQOL alone as an outcome in the era of 
novel therapies and recommends a focused and flexible 
approach to PRO measure selection. The PROMIS suite and 
PRO-CTCAE (Patient Reported Outcome Common Termi-
nology Criteria for Adverse Events) have been identified as 
being well-suited to this measurement approach.36
PRO administration
Trial staff experiences
A UK study about trial staff members’ experiences with PRO 
studies, across a range of health conditions, found that the 
trial team members felt they lacked guidance and training 
for PRO studies. A problematic issue relating to concerning 
PRO data, for example very high anxiety scores or par-
ticipants’ unsolicited comments about their PRO scores on 
questionnaire sheets, was highlighted. Trial staff noted that 
trial protocols and training rarely addressed how to respond 
in these situations.39
An Australian study of 20 cancer clinical trial coordina-
tors revealed that PRO administration procedures were often 
unclear regarding participants who were unable to complete 
questionnaires in English, handling participants’ family 
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members who attempted to complete PRO measures, whether 
to approach participants who appeared unwell or distressed, 
how to handle concerning PRO responses, and being flex-
ible to participants’ needs while also adhering to protocol 
procedures.40 Coordinators were uncertain how to respond 
to these challenges, particularly if they perceived a discord 
between their duty of care and their trial coordinator role, 
or if they had received conflicting instructions previously. 
For example, whether to act on a concerning PRO score if 
instructed not to check completed questionnaires.40
Poor PRO administration practices were common. Trial 
participants were often not fully informed about the nature 
of their research participation, for example, if PROs were not 
addressed at the trial consent stage, or if the purpose of PRO 
assessments was not discussed at all. The timing and mode of 
PRO administration often departed from the protocol. Some 
sites failed to train back-up personnel for when primary trial 
coordinators were absent from work, leading to missing PRO 
data during the primary coordinator’s absence.40
Furthermore, PRO training was a key concern. Only 
two of the 20 coordinators interviewed had received PRO-
specific training, and two others received no PRO training 
whatsoever.40 PRO training was more frequently provided by 
colleagues or briefly addressed at trial start-up meetings. As 
a result, trial coordinators often received inconsistent guid-
ance regarding PRO administration, leading to confusion 
and use of inconsistent methods. Despite this, 55% of trial 
 coordinators felt they did not need further PRO administration 
training40 in contrast to the UK study,39 which may present 
a barrier to their future attendance of PRO training courses. 
The general lack of PRO training reported by many of the 
coordinators interviewed raises concerns about the extent to 
which trial sponsors are complying with the good clinical 
practice guideline that trial staff must be adequately trained.41
Modes of administration
There is an extensive literature regarding different modes of 
questionnaire administration, comparing both the methods 
(such as paper-based, electronic [computer, smartphone, or tab-
let], telephone interview, etc.) and setting (home and clinic) of 
administration. In our experience, paper-based and electronic 
modes of administration are most commonly used methods. 
Pros and cons of each method are presented in Table 1.
A recent meta-analysis found no difference in patient 
responses (bias) between electronic and paper-based methods 
when the patient self-completed questionnaires. The authors 
concluded that self-completed questionnaires originally 
developed for paper-based administration could safely be 
administered by electronic modes, or both modes could 
be used in any one study. However, when self-completed 
Table 1 Pros and cons of paper and electronic modes of administration
Paper-based administration Electronic administration
Pros Cons Pros Cons
•	 Convenient for patients to 
complete while in clinic without 
needing to log-in/access 
technology
•	 if completed and collected in one 
place, the risk of losing completed 
questionnaires is reduced
•	 Reduced risk of technical errors
•	 Possible to complete 
questionnaires anywhere
•	 No need for computer literacy or 
internet access
•	 Data entry by hand is time-
consuming and prone to 
human error
•	 Data entry by scanning has 
high setup costs
•	 Storage in two formats 
may be required: hardcopy 
(physical) + electronic
•	 when completed at home, 
returning by post is costly 
and there is a risk of 
questionnaires not being 
returned or getting lost in the 
mail
•	 Links to questionnaires and 
reminders can be sent by email, 
which may save time and cost of 
hiring a research assistant
•	 Data entry and checking 
processes are streamlined 
and automated (at the time of 
completion of the questionnaire)
•	 Skip logic (iF Yes THeN more 
detail; iF No, THeN Skip) and 
“Computer-adaptive testing” 
(CAT) may be implemented 
to reduce patient burden and 
increase precision of the estimate
•	 Option of tablet/computer in 
clinic or completion at home
•	 increased potential to access 
participants in rural, remote, or 
international locations
•	 May be programed to ensure no 
items are missed (reduce item-
level missing PRO data)
•	 Patients can ignore or 
inadvertently miss email 
reminders
•	 Requires computer literacy and 
internet access
•	 Technical errors are possible 
(server or connectivity issues)
•	 Database setup, management, and 
maintenance costs may be high
•	 Location of server (if abroad) may 
be an issue for some studies in 
terms of ethical review
Abbreviation: PRO, patient-reported outcomes.
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questionnaire data (paper or electronic administration) was 
compared to administered modes (ie, questionnaire admin-
istered by a researcher over the phone or face-to-face), 
there was a slight difference in responses according to the 
administration setting (at home vs in clinic). Therefore, the 
authors recommended that if using self-complete and admin-
istered modes, the setting of administration should be kept 
consistent.42 Future meta-analyses are needed to determine 
whether mode of administration impacts questionnaire return 
rate or participant retention and whether the questionnaire 
return method (ie, returning to a coordinating center rather 
than to the recruitment site) impacts responses or return rate.
Burden associated with PRO assessment
It is important that investigators consider the extent to which 
PRO assessment may become burdensome to participants, 
trial staff, and statisticians. Unnecessary burden must be 
minimized. PRO assessment may become burdensome in a 
number of ways, as detailed in Table 2.
PRO administration guidance
Trial staff should receive clear PRO administration instruc-
tions in order for PROs to be administered consistently. 
Impressing the critical importance of PROs to the inter-
pretation of trial results to trial coordinators and clinicians 
is required before the trial begins. Consensus guidelines 
for PRO administration are lacking, although many good 
examples of guidance developed by individual groups exist. 
For example, the European Organization for the Research 
Table 2 How PRO assessment can become unnecessarily burdensome for trial participants and staff
Unnecessary burden on participants Unnecessary burden on trial staff
•	 Questionnaires may be too long
•	 Questions may be

	 Repetitive (particularly if multiple questionnaires are used and these assess the 
same or similar concepts)

	 irrelevant to the participant’s condition

	 intrusive (of a personal nature) for some participants

	 Poorly worded (eg, single questions may address multiple concepts)

	 Difficult; ie, wording may include difficult terminology for some participants or 
may be targeted at the incorrect reading level (lower reading levels are typically 
recommended)
•	 PRO assessments may be too frequent, causing even brief questionnaires to become 
burdensome
•	 Response options may be unclear (ie, scale numbers provided without scale anchors 
[not at all – very much]
•	 The mode of administration may be burdensome to participants (eg, if the 
participants must attend the clinic simply to complete a questionnaire, or log-in 
procedures for online assessment may be difficult for some participants)
•	 Participants may not understand the purpose for PRO assessment if this is not 
explained to them, which may contribute to feelings of burden
•	 Trial staff do not understand the purpose of PRO 
assessment due to poor training
•	 PRO data are collected but never analyzed or reported
•	 Trial staff need to provide high levels of assistance to 
participants due to a poorly chosen questionnaire, 
poorly worded questions, or difficult or time-intensive 
administration method
•	 Assessments are too long, frequent, or repetitive
•	 The return method involves scanning a double-sided or 
stapled booklet41
Abbreviation: PRO, patient-reported outcomes.
and Treatment of Cancer (EORTC) guidelines,43 the South 
West Oncology Group (SWOG) Training Module, presented 
by Dr Lisa Hansen (available for SWOG trials), and the QOL 
Office Checklist of instructions for the administration of 
PRO measures.44 Future research should develop consensus-
based PRO administration guidance and test the efficacy of 
accompanying training interventions.
Experienced clinical trial groups such as SWOG45 and the 
Epidemiology of Diabetes Interventions and Complications 
group46 have seen benefits including increased PRO compli-
ance, improved work satisfaction, and participant retention, 
as a result of involving trial coordinators or researcher nurses 
more actively in the research process and investing more 
resources in their professional development. These groups 
also engage experienced coordinators in training new coor-
dinators. A more formal approach to peer-training may be a 
feasible and acceptable approach to future trial coordinator 
training efforts for PRO administration.
Missing PRO data
issues with current practice
It is important to minimize the rates of missing data in 
clinical trials. High rates of missing PRO data can reduce 
study power,47 inflate risk of type 2 error,48 bias interpreta-
tion,47 and potentially undermine randomization.49 Fielding 
et al determined that 18% of RCTs published in the four 
highest-impact medical journals between 2005 and 2006 
had missing PRO data rates exceeding 20%, and a further 
20% of trials failed to clearly report rates of missing PRO 
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data.50 In many cases, the methods used to address missing 
PRO data in these trials were unclear or unsatisfactory.50 In 
an update of this review (2013–2014), ~8% of RCTs pub-
lished in high-impact journals used complete case analysis 
for PROs51 despite the inappropriateness of this approach 
in many contexts.52,53 Furthermore, the rate of missing PRO 
data was unclear in 35% of studies, 10% of trials had >20% 
missing PRO data, and only 13% indicated the missing data 
mechanism51 (system for classifying missing data according 
to their cause).48,54,55 It is important to deduce and report the 
missing data mechanism because this allows researchers to 
handle missing data appropriately, to select appropriate analy-
sis methods, and to interpret results with caution. Often the 
missing data mechanism has a stronger impact on the results 
than does the proportion of missing data.52,56 For example, 
if analysis methods assume that missing data are not related 
to the patients’ illness (eg, as with “complete case” analysis 
methods), when in fact the illness may have led to the data 
not being available, the results may falsely indicate that the 
outcome is favourable (resulting in bias). It is impossible to 
determine the true missing data mechanism, but information 
about the clinical status of the patient or the reasons for miss-
ing data, particularly whether these reasons are related to the 
patient’s worsening illness or not, can assist researchers in 
deducing the underlying mechanism.52
A review of the rates of missing PRO data in 36 ovarian 
cancer trials found similar problems to those noted above.57 
Many of these trials included patients with advanced/recur-
rent ovarian cancer, which may be associated with early 
progression and high mortality. Hence, a degree of missing 
data or trial drop out is expected to be related to worsening 
health status of the trial participants. It is concerning that 
the reasons for missing PRO data were indiscernible for 
72% of the publications studied. In the 10 RCTs (28%) that 
transparently reported PRO compliance rates (ie, those that 
differentiated between avoidable and informative sources 
of missing data), the percentages of avoidable missing PRO 
data were at times very high. The worst compliance rate 
was 59% (ie, 41% of trial participants had avoidable miss-
ing data (not illness-related). This suggested that trials did 
not sufficiently implement strategies to minimize avoidable 
missing PRO data. Analysis of the corresponding trial pro-
tocols for 26 of these 36 RCTs (72%) determined that trials 
that had less complete PRO protocol sections (ie, addressed 
the lowest number of recommended PRO protocol checklist 
items) had the highest rates of avoidable missing PRO data. 
This suggests a plausible link between the quality of PRO 
content of the protocol and the quality of PRO data collected, 
highlighting the importance of comprehensively addressing 
PROs in the trial protocol.57
Palmer et al developed a classification framework for 
factors associated with missing PRO data. This framework 
includes five categories: instrument (questionnaire content, 
length, language, etc.), participant (disease stage, physical 
impairment, refusal, etc.), center (infrastructure, location, 
etc.), staff (interpersonal skills, knowledge, motivation, etc.), 
and study-related factors (frequency and timing of assess-
ment, mode of administration, type of treatment, etc.).58 
Due to a majority of studies failing to report the reasons for 
missing PRO data, it is impossible to reliably estimate the 
rates of missing data attributed to these different categories. 
Research conducted in the late 1990s suggested that logistic 
and administrative errors caused a larger problem with respect 
to missing PRO data than patient-related and design factors.59
Guidance available on missing PRO data
Although methods exist to address problems with missing 
data statistically,60,61 it is better practice to prevent avoidable 
types of missing PRO data, such as staff failing to provide 
the questionnaires to patients, whenever possible, and to also 
clearly report the rates, reasons, and handling of missing PRO 
data in publications.55
A large systematic review of strategies for minimizing 
the problem of missing PRO data revealed how the whole 
trial team can actively reduce the problems of missing PRO 
data across all research stages.55 The strategies during study 
design include: specifying a clinically informative and 
feasible PRO assessment schedule with defined acceptable 
time windows and stopping rules, collecting auxiliary data 
(clinically relevant variables that are likely to be correlated 
to PRO data and recorded at the same time points) to facili-
tate unbiased interpretation of PRO data in the presence of 
missing data and inform statistical imputation of missing 
PRO data, specifying clear eligibility criteria for the PRO 
study including literacy and language requirements and the 
need for a valid baseline PRO assessment, ensuring that the 
PRO study is feasible and adequately resourced, ensuring the 
mode of questionnaire administration is feasible and accept-
able, minimizing participant burden, selecting a clinically 
relevant and validated PRO measure, incorporating PROs 
into all relevant trial documents, involving patient partners 
and trial staff in the design of PRO studies, ensuring that the 
trial team is committed to the PRO study, developing quality 
assurance procedures, ensuring that the PRO sample size 
is representative and sufficient for planned analyses, and 
involving a multidisciplinary team into PRO study design.55
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Implementation strategies include: developing standard-
ized PRO administration procedures, educating and engaging 
participants, maintaining patient records, appointing a site 
coordinator responsible for PRO assessment at each recruit-
ing site, ensuring that the trial team remains engaged and 
committed to the PRO study, and training trial staff.55
Reporting strategies for addressing the problem of 
missing PRO data include: clearly reporting study and PRO 
analysis methods, describing the sample -including baseline 
PRO scores, defining and providing PRO compliance rates, 
comparing participants with and without missing PRO data, 
providing reasons for missing data, and discussing the impact 
of missing data on generalizability.55
Analysis
issues with analysis of PRO studies
A major challenge for the analysis of PRO data is that many 
different analytic approaches are available, which has caused 
confusion for researchers, statisticians, clinicians, and oth-
ers about the most appropriate methods and how results 
should be interpreted. The methodology to be used should 
be determined a priori and included in the protocol with 
more detailed elaboration of analysis methods provided in 
the statistical analysis plan.
PRO analysis guidance
The ongoing “Setting International Standards in Analyzing 
Patient-Reported Outcomes and Quality of Life Endpoints 
Data” (SISAQOL)62 initiative is developing recommenda-
tions for standardized analysis and interpretation of PROs 
in cancer clinical trials, based on international and mul-
tidisciplinary consensus, which should become available 
within the next few years. This initiative acknowledges the 
challenges in using analysis methods that are suited to the 
PRO research question, statistically correct, handle missing 
data appropriately, transparent to clinicians, and comparable 
with results of other trials in systematic reviews.62
Reporting
issues with reporting of PRO studies
Readers must be able to appraise the design, analysis, and 
interpretation of a PRO study from its publication; there-
fore, transparent reporting is essential. In recent years, 
numerous studies have scrutinized the reporting of PROs 
in clinical trials, using various checklists of recommended 
reporting items,35,57,63–69 as summarized in Table 3. Table 3 
shows variation across various RCT cohorts studied as to 
how comprehensively studies were reported, (overall and at 
the item level). Items that were repeatedly poorly reported 
included: PRO hypotheses with PRO domains, approaches to 
handling missing PRO data, and discussions of limitations of 
the PRO study. In contrast, the reviews found that evidence 
of the validity of the PRO measures was typically provided.
Failure to report PRO endpoints is also an area of concern. 
Schandelmaier et al found that only 20% of 173 oncology 
RCTs with a PRO endpoint listed in the protocol subse-
quently reported PRO findings.70 The authors suggested that 
trial discontinuation was significantly associated with both 
failure to report any PRO data and failure to report PROs as 
specified in the protocol.70 Schandelmaier et al’s study was 
based on RCTs approved by six ethics committees from 
three countries, and results may therefore not represent the 
rate of PRO reporting internationally.70 However, the issue of 
non-reporting of PROs is emerging and requires attention, as 
it is unethical to waste the funding, resources, and patients’ 
efforts expended in PRO data collection.71
PRO reporting guidance
The International Society for Quality of Life Research 
(ISOQOL) published comprehensive reporting standards in 
2013,72 consisting of 29 items, 11 of which are only relevant 
to RCTs with primary PRO endpoints and 18 are relevant 
to trials with either primary or secondary PRO endpoints. 
This work informed the development of a CONSORT-PRO 
Extension (Consolidated Standards of Reporting Trials), 
which can be considered the minimum reporting items 
for PRO endpoints (primary or key secondary) in RCTs.73 
CONSORT-PRO consists of 14 items, five of which were 
newly developed PRO-specific reporting recommendations 
(eg, the PRO should be identified in the abstract as primary 
or secondary outcome, provide evidence of validity of PRO 
measures, and report statistical approaches for dealing with 
missing PRO data). The remaining nine CONSORT-PRO 
items are elaborated from the CONSORT-201074 statement 
to specifically address PROs.
Table 3 shows that RCTs published after the release 
of CONSORT-PRO73 generally had higher rates of report-
ing on most criteria, particularly those RCTs which cited 
CONSORT-PRO.69 This suggests a preliminary benefit of 
CONSORT-PRO in improving the standard of reporting; 
however, given that some RCTs that used CONSORT-PRO 
had incomplete reporting, additional knowledge transfer 
efforts are needed.69 It is encouraging to note that a number 
of high-ranking journals now request evidence of compliance 
with the CONSORT-PRO checklist for publications reporting 
PRO endpoints.
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Table 3 Completeness of PRO reporting in RCTs – results from nine evaluations
Review publication and 
reporting checklist used
Joly et al67 Brundage et al63 Efficace et al66,a Bylicki et al64 Efficace et al65 Mercieca-Bebber et al35,a Mack et al68 Mercieca-Bebber et al57 Mercieca-Bebber et al69
Reporting checklist used Study-specific criteria Study-specific criteria The iSOQOL reporting 
standards, Brundage et al72
The CONSORT-PRO 
extension, Calvert et al73
The CONSORT-PRO 
extension, Calvert et al73
The iSOQOL reporting 
standards, Brundage et al72
The CONSORT-PRO 
extension, Calvert et al73
The CONSORT-PRO 
extension, Calvert et al73
The CONSORT-PRO 
extension, Calvert et al73
Publication sample reviewed 112 Phase iii advanced 
cancer RCTs published 
from 1994 to 2004
381 oncology RCTs 
published from 2002 
to 2008
50 gynecological cancer 
RCTs published from 
2004 to June 2012 
(PROMOTiON registry)
124 Phase iii medical 
oncology RCTs 
published from 2007 
to 2011
557 RCTs in the 
PROMOTiON registry
66 head and neck, thyroid 
cancer RCTs published from 
2004 to 2015 (PROMOTiON 
registry)
23 exercise interventions 
for individuals living with 
osteoporosis
36 Phase iii ovarian cancer 
RCTs published from 2000 
to February 2016
66 RCTs published post 
CONSORT-PRO; from 2013 
to 2015 (case/control)
PRO identified as outcome in 
abstract
N/A N/A 76% 28% 81% 83% 91% 69% 96%/59%
Rationale for PRO assessment N/A N/A N/A 43% N/A N/A 35% 42% 85%/93%
PRO hypothesis including domains 19% 55% 10% 26% 7% 22% 39%
(83% including domains)
19% 73%/23%
(including domains: 50%/15%)
Statement on who completed the 
instrument
N/A 53% N/A 38% N/A N/A 61% 53% 81%/78%
Mode of PRO administration N/A N/A 16% 16% 24% 12% 9% 6% 35%/25%
Rationale for choice of the PRO 
instrument
N/A 56% 16% N/A N/A 24% N/A N/A N/A
evidence of PRO instrument validity 85% (use of a validated 
questionnaire)
76% 76% 36% 71% 58% 48% 64% 92%/73%
PRO data collection schedule N/A N/A 84% N/A N/A 73% N/A N/A N/A
PRO endpoint status 22% (definition of 
a primary palliative 
endpoint)
N/A 88% (status of PRO as 
either a primary or a 
secondary outcome)
28% (based on abstract 
only) N/A – within 
manuscript text
N/A 82% N/A 47% (based on abstract only) 
N/A – within manuscript 
text
38%/38% (based on 
abstract only) N/A – within 
manuscript text
Definition of a palliative response 24% N/A N/A N/A N/A N/A N/A N/A N/A
PRO sample size or power 
calculations
N/A 17% Only reported for RCTs 
with primary PRO endpoint
N/A N/A 59% (primary endpoint only) 17% N/A N/A
evidence of appropriate PRO 
statistical analysis + significance
N/A N/A 10% N/A N/A 88% N/A N/A N/A
Number of patients included in 
analysis
N/A N/A N/A N/A N/A N/A 100% 64% 81%/75%
Statistical corrections when multiple 
comparisons are made
10% N/A Only reported for RCTs 
with primary PRO endpoint
N/A N/A 31% N/A N/A N/A
Flow diagram/description of 
allocation of participants and those 
lost to PRO follow-up
N/A 42% 32% PRO outcome data 
available at baseline: 61%
At subsequent time 
points: 70%
N/A 26% PRO outcome data 
available at baseline: 91%
At subsequent time points: 
95%
PRO outcome data available 
at baseline: 50%
At subsequent time points: 
47%
PRO outcome data available 
at baseline: 73%/68%
At subsequent time points: 
81%/73%
Participants’ characteristics 
described, including baseline PRO 
scores
N/A N/A 62% 40% N/A 42% 96% 36% 73%/85%
extent of missing data N/A N/A 60% 48% N/A 29% N/A 72% (28% adequately/46% 
incompletely)
81%/73%
Reasons for missing data N/A N/A 30% N/A N/A 26% N/A N/A N/A
Approach to/handling of missing data 
described
16% 25% 18% 37% 20% 18% 13% 39% 77%/50%
For multidimensional PRO results 
from each domain and time point
25% (comparison of 
changes in QOL or 
a symptom scale for 
individual patients, instead 
of comparison of mean 
QOL scores)
N/A N/A 43% N/A 82% (of primary PRO endpoint 
only)
91% 72% 92%/85%
Results include Ci or effect size N/A N/A N/A N/A N/A N/A 35% 44% 81%/75%
PROs reported in graphical format N/A N/A N/A N/A N/A 46% N/A N/A N/A
Results subgroup/exploratory 
analyses
N/A N/A N/A N/A N/A N/A 22% 39% 54%/45%
Proportion of patients who achieved 
a palliative response
21% N/A N/A N/A N/A N/A N/A N/A N/A
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Table 3 Completeness of PRO reporting in RCTs – results from nine evaluations
Review publication and 
reporting checklist used
Joly et al67 Brundage et al63 Efficace et al66,a Bylicki et al64 Efficace et al65 Mercieca-Bebber et al35,a Mack et al68 Mercieca-Bebber et al57 Mercieca-Bebber et al69
Reporting checklist used Study-specific criteria Study-specific criteria The iSOQOL reporting 
standards, Brundage et al72
The CONSORT-PRO 
extension, Calvert et al73
The CONSORT-PRO 
extension, Calvert et al73
The iSOQOL reporting 
standards, Brundage et al72
The CONSORT-PRO 
extension, Calvert et al73
The CONSORT-PRO 
extension, Calvert et al73
The CONSORT-PRO 
extension, Calvert et al73
Publication sample reviewed 112 Phase iii advanced 
cancer RCTs published 
from 1994 to 2004
381 oncology RCTs 
published from 2002 
to 2008
50 gynecological cancer 
RCTs published from 
2004 to June 2012 
(PROMOTiON registry)
124 Phase iii medical 
oncology RCTs 
published from 2007 
to 2011
557 RCTs in the 
PROMOTiON registry
66 head and neck, thyroid 
cancer RCTs published from 
2004 to 2015 (PROMOTiON 
registry)
23 exercise interventions 
for individuals living with 
osteoporosis
36 Phase iii ovarian cancer 
RCTs published from 2000 
to February 2016
66 RCTs published post 
CONSORT-PRO; from 2013 
to 2015 (case/control)
PRO identified as outcome in 
abstract
N/A N/A 76% 28% 81% 83% 91% 69% 96%/59%
Rationale for PRO assessment N/A N/A N/A 43% N/A N/A 35% 42% 85%/93%
PRO hypothesis including domains 19% 55% 10% 26% 7% 22% 39%
(83% including domains)
19% 73%/23%
(including domains: 50%/15%)
Statement on who completed the 
instrument
N/A 53% N/A 38% N/A N/A 61% 53% 81%/78%
Mode of PRO administration N/A N/A 16% 16% 24% 12% 9% 6% 35%/25%
Rationale for choice of the PRO 
instrument
N/A 56% 16% N/A N/A 24% N/A N/A N/A
evidence of PRO instrument validity 85% (use of a validated 
questionnaire)
76% 76% 36% 71% 58% 48% 64% 92%/73%
PRO data collection schedule N/A N/A 84% N/A N/A 73% N/A N/A N/A
PRO endpoint status 22% (definition of 
a primary palliative 
endpoint)
N/A 88% (status of PRO as 
either a primary or a 
secondary outcome)
28% (based on abstract 
only) N/A – within 
manuscript text
N/A 82% N/A 47% (based on abstract only) 
N/A – within manuscript 
text
38%/38% (based on 
abstract only) N/A – within 
manuscript text
Definition of a palliative response 24% N/A N/A N/A N/A N/A N/A N/A N/A
PRO sample size or power 
calculations
N/A 17% Only reported for RCTs 
with primary PRO endpoint
N/A N/A 59% (primary endpoint only) 17% N/A N/A
evidence of appropriate PRO 
statistical analysis + significance
N/A N/A 10% N/A N/A 88% N/A N/A N/A
Number of patients included in 
analysis
N/A N/A N/A N/A N/A N/A 100% 64% 81%/75%
Statistical corrections when multiple 
comparisons are made
10% N/A Only reported for RCTs 
with primary PRO endpoint
N/A N/A 31% N/A N/A N/A
Flow diagram/description of 
allocation of participants and those 
lost to PRO follow-up
N/A 42% 32% PRO outcome data 
available at baseline: 61%
At subsequent time 
points: 70%
N/A 26% PRO outcome data 
available at baseline: 91%
At subsequent time points: 
95%
PRO outcome data available 
at baseline: 50%
At subsequent time points: 
47%
PRO outcome data available 
at baseline: 73%/68%
At subsequent time points: 
81%/73%
Participants’ characteristics 
described, including baseline PRO 
scores
N/A N/A 62% 40% N/A 42% 96% 36% 73%/85%
extent of missing data N/A N/A 60% 48% N/A 29% N/A 72% (28% adequately/46% 
incompletely)
81%/73%
Reasons for missing data N/A N/A 30% N/A N/A 26% N/A N/A N/A
Approach to/handling of missing data 
described
16% 25% 18% 37% 20% 18% 13% 39% 77%/50%
For multidimensional PRO results 
from each domain and time point
25% (comparison of 
changes in QOL or 
a symptom scale for 
individual patients, instead 
of comparison of mean 
QOL scores)
N/A N/A 43% N/A 82% (of primary PRO endpoint 
only)
91% 72% 92%/85%
Results include Ci or effect size N/A N/A N/A N/A N/A N/A 35% 44% 81%/75%
PROs reported in graphical format N/A N/A N/A N/A N/A 46% N/A N/A N/A
Results subgroup/exploratory 
analyses
N/A N/A N/A N/A N/A N/A 22% 39% 54%/45%
Proportion of patients who achieved 
a palliative response
21% N/A N/A N/A N/A N/A N/A N/A N/A
(Continued)
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Review publication and 
reporting checklist used
Joly et al67 Brundage et al63 Efficace et al66,a Bylicki et al64 Efficace et al65 Mercieca-Bebber et al35,a Mack et al68 Mercieca-Bebber et al57 Mercieca-Bebber et al69
Duration of palliative response 51% N/A N/A N/A N/A N/A N/A N/A N/A
PRO-specific limitations and 
implications
51% N/A 46% 35% 46% 21% 35% 36% 77%/75%
PRO generalizability issues N/A N/A 28% N/A 18% 65% 53% 81%/83%
The clinical significance of the PRO 
findings
N/A N/A 30% N/A N/A 26% N/A N/A N/A
PRO results should be discussed/
interpreted in the context of the 
other clinical trial outcomes
N/A 65% 44% 60% N/A 55% 83% 69% 81%/85%
Notes: Percentages reported indicate the percentage of trials from each review that addressed that criterion; N/A, not assessed; aReporting criteria for trials with a  
primary PRO endpoint only are not reported here.
Abbreviations: PRO, patient-reported outcome; QOL, quality of life; RCT, randomized controlled trial; iSOQOL, international Society for Quality of Life Research;  
CONSORT-PRO extension, Consolidated Standards of Reporting Trials – Patient-reported outcome extension; PROMOTiON, patient reported outcomes over time in  
oncology.
Table 3 (Continued)
Guidance across PRO research stages
We encourage readers to access these key resources, which 
provide excellent guidance across research stages:
•	 Fairclough DL. Design and Analysis of Quality of Life 
Studies in Clinical Trials. 2nd ed. boca raton, FL: Taylor 
and Francis Group; 2010.
•	 Fayers P, Machin D. Quality of Life: The Assessment, 
Analysis and Interpretation of Patient-Reported Out-
comes. 2nd ed. Chichester, UK: John Wiley & Sons; 2007.
•	 The Center for Patient Reported Outcomes Research 
(CPROR) PROlearn resources: Available from: www.
birmingham.ac.uk/prolearn.
Conclusion
Ongoing methodological research is important for deter-
mining what constitutes best practice in PRO research and 
adhering to those standards. High-quality clinical trials 
inform clinical practice and policy. Therefore, researchers 
and clinical trial investigators must implement evidence-
based strategies to promote high-quality PRO data collec-
tion, analysis, and reporting of PRO evidence. This process 
must begin with improved, PRO-specific education for 
trial team members about the core principles and methods 
for PRO research, with particular focus on strategies to 
minimize the frequency and effects of missing data. PRO 
aspects of trial protocols should be developed in accordance 
with the SPIRIT-PRO guidance.29 Multidisciplinary teams, 
including patient partners, must be involved in the design 
of PRO aspects of clinical trials to ensure that scientific, 
logistic, and resource considerations are addressed with 
high-quality, complete data collection in mind. Clini-
cally informative, valid, and reliable PRO measures and 
time points for assessment should be carefully chosen to 
address the PRO hypotheses. A plan to facilitate handling 
of unavoidable and/or informative missing data should 
be employed, particularly in trials involving participants 
with advanced disease who are unlikely to complete all 
scheduled follow-up assessments. Trials should incorporate 
ongoing quality assurance measures. PRO findings should 
be published according to CONSORT-PRO and ISOQOL 
PRO reporting guidelines,72,75 in a timely manner. If the 
PRO results are to be published separately, the primary trial 
publication should reference, or at least acknowledge the 
forthcoming PRO publication. Each trial publication should 
be clearly labeled with the trial name/number for ease of 
identification and to facilitate joint interpretation of PRO 
and other trial outcomes. Funders, ethics committees, jour-
nals, and trial sponsors should proactively ensure that PRO 
studies are designed, conducted, analyzed, and reported to 
these standards; this can only be achieved with their active 
engagement in such efforts. If all these stakeholders play 
their role, the result will be high-quality PRO evidence, 
integrated with other trial outcomes, to better inform clinical 
decision-making and health care policy.
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Duration of palliative response 51% N/A N/A N/A N/A N/A N/A N/A N/A
PRO-specific limitations and 
implications
51% N/A 46% 35% 46% 21% 35% 36% 77%/75%
PRO generalizability issues N/A N/A 28% N/A 18% 65% 53% 81%/83%
The clinical significance of the PRO 
findings
N/A N/A 30% N/A N/A 26% N/A N/A N/A
PRO results should be discussed/
interpreted in the context of the 
other clinical trial outcomes
N/A 65% 44% 60% N/A 55% 83% 69% 81%/85%
Notes: Percentages reported indicate the percentage of trials from each review that addressed that criterion; N/A, not assessed; aReporting criteria for trials with a  
primary PRO endpoint only are not reported here.
Abbreviations: PRO, patient-reported outcome; QOL, quality of life; RCT, randomized controlled trial; iSOQOL, international Society for Quality of Life Research;  
CONSORT-PRO extension, Consolidated Standards of Reporting Trials – Patient-reported outcome extension; PROMOTiON, patient reported outcomes over time in  
oncology.
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